Mutations in RAS pathway induce synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia

Microarray experiment for pharmacogenomics profilling. Two mutations, an NF1 knockout and NRAS G12D, that induce the RAS signalling pathway were made in TF1 cells. The NRAS G12D mutant was treated with pyrvinium at 250 nM in DMSO (vehicle).